A new $11.7 million Washington University MPN grant will help researchers investigate a question that matters to patients: can targeting inflammation help keep an MPN from getting worse? The award, announced September 29, 2026, comes from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. Stephen T. Oh, MD, PhD, […]
Polycythemia Vera Hematocrit: Is Below 45% Enough?
By David Wallace – Patient perspective | September 25, 2026 The established polycythemia vera hematocrit target is below 45%. That goal lowers the risk of serious blood clots and cardiovascular death. It does not necessarily mean symptom relief. I learned that the hard way. My circulation-related symptoms often started around 42%, well before I hit the […]
Mimrylo Earns NCCN Category 1 Recommendation for PV
By David Wallace – September 23, 2026 Mimrylo (rusfertide) has been added as a Category 1 treatment option for both low- and high-risk polycythemia vera (PV) in the National Comprehensive Cancer Network’s updated guidelines. For patients who need frequent phlebotomies, the update is another reason to ask whether a medicine designed to control hematocrit could […]
FDA Approves BESREMi for Essential Thrombocythemia (ET)
By David Wallace | September 13, 2026 The FDA approved BESREMi for essential thrombocythemia on August 31, 2026, giving adults with ET their first new FDA-approved treatment in nearly 30 years. BESREMi (ropeginterferon alfa-2b-njft) is a long-acting interferon given by injection every two weeks. If hydroxyurea is not controlling your disease or its side effects […]